NCT03784677 - A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 29, 2019

Primary Completion Date

June 20, 2023

Study Completion Date

June 20, 2023

Conditions

Advanced Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRefractory Ovarian CarcinomaRefractory Pancreatic CarcinomaStage II Pancreatic Cancer AJCC v8Stage IIA Pancreatic Cancer AJCC v8Stage IIB Pancreatic Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IIIA Ovarian Cancer AJCC v8Stage IIIA Prostate Cancer AJCC v8Stage IIIB Ovarian Cancer AJCC v8Stage IIIB Prostate Cancer AJCC v8Stage IIIC Ovarian Cancer AJCC v8Stage IIIC Prostate Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Stage IV Prostate Cancer AJCC v8Stage IVA Ovarian Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Ovarian Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8

Interventions

DRUG

TRPV6 Calcium Channel Inhibitor SOR-C13

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER